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Background 
Multi-parameter genomic tests may identify patients with early breast cancer who derive 
little benefit from adjuvant chemotherapy. They offer the potential to spare patients morbidity from 
unnecessary chemotherapy and reduce costs. Costs of the test must, however, be balanced against 
the health benefits and costs savings produced. This economic evaluation compares test-directed 
chemotherapy with chemotherapy for all eligible patients with lymph node positive, oestrogen 
receptor positive early breast cancer, using the Oncotype-DX 21-gene assay.  
Methods 
A cost-effectiveness analysis was performed using a probabilistic decision model to calculate 
expected costs and benefits over the lifetime of a cohort of women with average clinical 
characteristics. Recurrence rates for test- selected risk-groups were based on the SWOG-8814 trial. 
The primary outcome was cost per quality adjusted life year (QALY). The perspective adopted for the 
analysis was the UK NHS.  
Findings 
The expected cost-effectiveness of test-directed therapy using Oncotype DX is £5921 per 
QALY with 18 as cut-off between high and low recurrence-scores. The probability that this is cost-
effective is 61% at a willingness-to-pay threshold of £30,000 per QALY.  Results are sensitive to the 
recurrence rate, long-term anthracycline-related cardiac toxicity, quality of life, test cost and the 
time-horizon considered. The priority for further research is the recurrence rates in subgroups 
selected by Oncotype DX or alternative tests.   
Interpretation 
There is substantial uncertainty regarding the cost-effectiveness of test-directed 
chemotherapy. There is a high societal value in further research to reduce this uncertainty. Priorities 
for research to inform cost-effectiveness based decision making have been identified.  
